Approval Summary: Imatinib Mesylate for One or Three Years in the Adjuvant Treatment of Gastrointestinal Stromal Tumors

On January 31, 2012, the U.S. Food and Drug Administration granted regular approval of imatinib mesylate tablets (Gleevec®; Novartis Pharmaceuticals Corporation, East Hanover, NJ) for the adjuvant treatment of adult patients following complete gross resection of Kit(+) (CD117(+)) gastrointestinal st...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Cohen, Martin H., Johnson, John R., Justice, Robert, Pazdur, Richard
Format: Artigo
Sprog:Inglês
Udgivet: AlphaMed Press 2012
Fag:
Regulatory Issues: FDA
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399657/
https://ncbi.nlm.nih.gov/pubmed/22643537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0109
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker